



Supplementary Information

**Human substance P receptor binding mode of the antagonist drug aprepitant by NMR
and crystallography**


S. Chen, M. Lu, D. Liu et al.




Supplementary Figure 1 | Electron densities of ligand and residues around position 2.50 in NK1R structures. **a** and **b**, Electron densities of aprepitant in the NK1R (E78^{2.50}D)-aprepitant structure (**a**) and NK1R (E78^{2.50}N)-aprepitant structure (**b**). The NK1R structure is shown in grey. The ligand is displayed as sticks with orange carbons. Electron densities are contoured at 3.0 σ from a $|Fo| - |Fc|$ omit map and coloured blue. **c** and **d**, Electron densities of the residues around the position 2.50 in the NK1R (E78^{2.50}D)-aprepitant structure (**c**) and NK1R (E78^{2.50}N)-aprepitant structure (**d**). The NK1R structure is shown in grey. The residues around the position 2.50 are displayed as green sticks. Electron densities are contoured at 1.0 σ from a $|2Fo| - |Fc|$ map and coloured blue.




Supplementary Figure 2 | Cell-surface expression of wild-type (WT) and mutant NK1 receptors in HEK293 cells. Data are shown as mean \pm s.e.m. from three independent experiments using independently transfected cells and performed in triplicate. Source data are provided as a Source Data file.




Supplementary Figure 3 | IP1 accumulation of wild-type NK1R (WT) and the E78^{2.50}D and E78^{2.50}N mutants in apo state and in the presence of aprepitant (at 1 μ M concentration) or SP (at 1 μ M concentration). Data shown are mean \pm s.e.m. from at least three independent experiments performed in technical triplicate. For E78^{2.50}N-apo and E78^{2.50}N-aprepitant, three independent experiments were performed. For the other samples, four independent experiments were performed. Source data are provided as a Source Data file.



Supplementary Figure 4 | Lorentzian deconvolution of the 1D ¹⁹F-NMR spectra. **a**, NMR spectra of aprepitant bound to four different NK1R mutants, as indicated. The blue line represents the experimental ¹⁹F-NMR signal. The components obtained by deconvolution are displayed with the following colour code: P1a, purple; P1b, green; M, grey; P2a, brown; P2b, pink; sum of the five deconvoluted peaks, red. **b**, Relative intensities of the component peaks.



Supplementary Figure 5 | Origin of ring current shifts for the trifluoromethyl group bound to aprepitant in NK1R and interaction network of aprepitant to NK1R. a, Notation of the trifluoromethyl groups in aprepitant. **b**, Location of aprepitant relative to the NK1R residues W261^{6.48}, F264^{6.51}, and F268^{6.55} that induce major ring current shifts of the trifluoromethyl groups. **c**, The corresponding positions of aprepitant to key residues of receptor activation.



Supplementary Figure 6 | Sequence alignment of the human neurokinin receptors. Colours

represent the degree of similarity of residues: red background, identical; red text, similar. Key

residues in the aprepitant binding pocket, which are conserved or variable among receptors, are

indicated by black and red arrows, respectively. The alignment was generated by uniprot

(<http://www.uniprot.org/align/>) and the graphic was prepared on the ESPrnt 3.0 server

(<http://esprnt.ibcp.fr/ESPrnt/cgi-bin/ESPrnt.cgi>).

Supplementary Table 1 | Data collection and structure refinement statistics.

	NK1R (E78 ^{2.50} D)-aprepitant	NK1R (E78 ^{2.50} N)-aprepitant
Data collection^a		
Space group	<i>P4₂2₁2</i>	<i>P4₂2₁2</i>
Cell dimensions		
<i>a, b, c</i> (Å)	103.1, 103.1, 158.2	102.5, 102.5, 157.0
α, β, γ (°)	90.0, 90.0, 90.0	90.0, 90.0, 90.0
Resolution (Å)	50.0-3.20 (3.37-3.20) ^b	50.0-2.70 (2.83-2.70)
<i>R</i> _{merge}	0.15 (0.77)	0.13 (0.99)
<i>I</i> / σ (<i>I</i>)	9.8 (2.1)	8.3 (1.1)
<i>CC</i> _{1/2}	0.99 (0.77)	0.99 (0.50)
Completeness (%)	92 (60)	95 (60)
Redundancy	12.1 (9.8)	9.2 (3.8)
Refinement		
Resolution (Å)	50.0-3.20	50.0-2.70
No. reflections	13,746	23,622
<i>R</i> _{work} / <i>R</i> _{free}	0.214 / 0.254	0.233 / 0.261
No. atoms		
Protein	3,115	3,147
Ligand	37	37
Others	19	0
<i>B</i> factors (Å ²)		
NK1R	125.6	117.4
mT4L	116.6	108.2
Ligand	107.7	99.5
R.m.s. deviations		
Bond lengths (Å)	0.010	0.009
Bond angles (°)	1.04	1.01

^aDiffraction data from 47 NK1R (E78^{2.50}D)-aprepitant crystals and 21 NK1R (E78^{2.50}N)-aprepitant crystals were used to solve the structures.

^bValues in parentheses are for highest-resolution shell.

Supplementary Table 2 | IP1 accumulation assays of wild-type (WT) and mutant NK1 receptors for the agonist SP and inhibition by aprepitant.

WT/mutants	SP ^a			SP/aprepitant ^b			Ratio ^e
	EC ₅₀ (nM)	pEC ₅₀ ± s.e.m. ^c	n ^d	EC ₅₀ (nM)	pEC ₅₀ ± s.e.m.	n	
WT	2.4	8.63 ± 0.06	4	117	6.93 ± 0.23	4	49
E78 ^{2.50} D ^f	2.7	8.57 ± 0.01	3	64	7.19 ± 0.02	3	24
N301 ^{7.49} Q	2.6	8.58 ± 0.02	3	71	7.15 ± 0.04	3	27
E78 ^{2.50} D/N301 ^{7.49} Q	2.7	8.57 ± 0.02	3	68	7.17 ± 0.05	3	25
E78 ^{2.50} N	2.5	8.60 ± 0.03	3	254	6.60 ± 0.27	3	102
N301 ^{7.49} E	4.0	8.39 ± 0.08	3	119	6.93 ± 0.93	3	30
E78 ^{2.50} N/N301 ^{7.49} E	2.5	8.61 ± 0.05	3	79	7.10 ± 0.03	3	32
I113 ^{3.33} M	3.1	8.52 ± 0.05	3	41	7.39 ± 0.09	3	13
V116 ^{3.36} M	2.8	8.55 ± 0.05	3	38	7.42 ± 0.10	3	14
Q165 ^{4.60} A	2.2	8.65 ± 0.03	3	27	7.56 ± 0.11	3	12
W184 ^{ECL2} L	2.4	8.62 ± 0.07	3	47	7.32 ± 0.11	3	20
E193 ^{5.35} H	2.1	8.68 ± 0.05	3	27	7.57 ± 0.20	3	13
H197 ^{5.39} L	3.2	8.50 ± 0.02	3	101	7.00 ± 0.19	3	32
I204 ^{5.46} V	2.7	8.57 ± 0.03	3	17	7.78 ± 0.23	3	6.2
F264 ^{6.51} Y	2.9	8.53 ± 0.02	3	18	7.74 ± 0.11	3	6.2
F264 ^{6.51} L	3.0	8.52 ± 0.06	3	46	7.34 ± 0.14	3	15
E78 ^{2.50} D/Y121 ^{3.41} W/ Q165 ^{4.60} A/T222 ^{5.64} R	3.0	8.52 ± 0.06	3	219	6.66 ± 0.15	3	73
E78 ^{2.50} N/Y121 ^{3.41} W /T222 ^{5.64} R	4.3	8.37 ± 0.02	3	163	6.79 ± 0.75	3	38

^aEC₅₀ values were determined after 0.5 h stimulation by increasing concentrations of SP.

^bEC₅₀ values were determined after 0.5 h stimulation by increasing concentrations of SP together with 100 nM aprepitant.

^cData represent mean ± s.e.m.

^dSample size; the number of independent experiments performed in technical triplicate or duplicate.

^eThe EC₅₀ ratio represents the shift between the SP and SP + aprepitant curve (EC₅₀(SP + aprepitant)/EC₅₀(SP)) and characterizes the antagonistic effect on the WT receptor or receptor mutants. By comparison of EC₅₀ ratios between WT and mutant receptors, influences of all tested residues on antagonist activity were determined. A higher ratio indicates higher antagonist activity. A reduced EC₅₀ ratio of mutant compared to the wild-type receptor was interpreted as important for the respective antagonist.

^fAll mutations were introduced to the WT NK1R.

Supplementary Table 3 | cAMP assays of wild-type (WT) and mutant NK1 receptors for the agonist SP.

WT/mutants	EC ₅₀ (nM)	pEC ₅₀ ± s.e.m. ^a	n ^b
WT	4.1	8.38 ± 0.04	4
E78 ^{2.50} D ^b	8.0	8.10 ± 0.07	3
N301 ^{7.49} Q	2.3	8.64 ± 0.06	4
E78 ^{2.50} D/N301 ^{7.49} Q	3.1	8.52 ± 0.04	3
E78 ^{2.50} N	18	7.76 ± 0.08	3
N301 ^{7.49} E	3.0	8.53 ± 0.13	3
E78 ^{2.50} N/N301 ^{7.49} E	2.3	8.65 ± 0.05	3

^aData represent mean ± s.e.m.

^bSample size; the number of independent experiments performed in technical triplicate.

^cAll mutations were introduced to the WT NK1R.

Supplementary Table 4 | ^{19}F ring current shifts for apreptitant in NK1R complexes.

Mutant	$\Delta\delta(\text{ppm})^{\text{a}}$	Pseudo atom ^b	$\delta_{\text{R}}(\text{ppm})^{\text{c}}$	Contributing residues (δ_{R} in ppm) ^d
$\text{E}^{2.50}\text{D}$	0.73 (P1)	F1	0.12	W261 (0.16), F264 (-0.11)
	-0.34 (P2)	F2	-0.18	W261 (-0.14), F268 (-0.10)
$\text{E}^{2.50}\text{N}$	1.04 (P1)	F1	0.28	W261 (0.19)
	-0.38 (P2)	F2	-0.29	W261 (-0.24), F268 (-0.06)

^aObserved chemical shift difference between receptor (P1, P2 in Fig. 4) and micelle-bound (M) peaks. Average values of the two polymorphism peaks are used (see Supplementary Figure 4).

^bRing current shifts for the trifluoromethyl groups were calculated for the pseudo-atom positions of F1, and F2 representing the three ^{19}F atoms. The Johnson–Bovey algorithm¹ in the program MOLMOL² was used.

^cCalculated ring current shifts.

^dNK1R residues with major contributions to δ_{R} .

Supplementary Table 5 | DNA sequence of the codon-optimized NK1R gene and primer sequences.

NK1R (E78 ^{2.50} D) gene sequence
GATAACGTCCTCCCGGTGGACTCAGACCTCTCCCCAAACATCTCCACTAACACCTCGG AACCCAATCAGTTCGTGCAACCAGCCTGGCAAATTGTCCTTTGGGCAGCTGCCTACAC GGTCATTGTGGTGACCTCTGTGGTGGGCAACGTGGTAGTGATGTGGATCATCTTAGCC CACAAAAGAATGAGGACAGTGACGAACTATTTTCTGGTGAACCTGGCCTTCGCGGAT GCCTCCATGGCTGCATTCAATACAGTGGTGAACCTCACCTATGCTGTCCACAACGAAT GGTACTACGGCCTGTTCTACTGCAAGTTCACAACCTTCTTTCCCATCGCCGCTGTCTTC GCCAGTATCTGGTCCATGACGGCTGTGGCCTTTGATAGGTACATGGCCATCATAACATC CCCTCCAGCCCCGGCTGTCAGCCACAGCCACCAAAGTGGTCATCTGTGTCATCTGGGT CCTGGCTCTCCTGCTGGCCTTCCCCGCGGGCTACTACTCAACCACAGAGACCATGCCC AGCAGAGTCGTGTGCATGATCGAATGGCCAGAGCATCCGAACAAGATTTATGAGAAA GTGTACCACATCTGTGTGACTGTGCTGATCTACTTCCTCCCCCTGCTGGTGATTGGCTA TGCATACACCGTAGTGGGAATCAGACTATGGGCTAGCAACATCTTCGAGATGCTGCGT ATCGATGAGGGAGGCGGCAGTGGCGGCGACGAGGCCGAAAAGTTGTTCAACCAGGA TGTGGACGCCGCCGTACGTGGAATTTTTCGTAACGCGAAGCTGAAGCCTGTCTATGAT AGCCTGGATGCTGTCAGACGTGCAGCCCTGATTAACATGGTGTTCCAAATGGGCGAG ACGGGAGTCGCAGGCTTCACCAATTCGCTCAGGATGCTCCAGCAAAAGCGTTGGGAT GAAGCAGCGGTCAACTTGCAAAGTCCAGATGGTACAACCAGACCCCTAACAGAGCC AAACGTGTGATCACCACCTTCAGGACCGGTACATGGGACGCTTACCACGAGCAAGTC TCTGCCAAGCGCAAGGTGGTCAAATGATGATTGTCGTGGTGTGCACCTTCGCCATCT GCTGGCTGCCCTTCACATCTTCTTCCTCCTGCCCTACATCAACCCAGATCTCTACCTG AAGAAGTTTATCCAGCAGGTCTACCTGGCCATCATGTGGCTGGCCATGAGCTCCACCA TGTAACAACCCCATCATCTACTGCTGCCTCAATGACAGGTTCCGTCTGGGCTTCAAGCA TGCCTTCCGGTGCTGCCCTTCATCAGCGCCGGCGACTATGAGGGGCTGGAA
NK1R (E78 ^{2.50} N) gene sequence
GATAACGTCCTCCCGGTGGACTCAGACCTCTCCCCAAACATCTCCACTAACACCTCGG AACCCAATCAGTTCGTGCAACCAGCCTGGCAAATTGTCCTTTGGGCAGCTGCCTACAC GGTCATTGTGGTGACCTCTGTGGTGGGCAACGTGGTAGTGATGTGGATCATCTTAGCC CACAAAAGAATGAGGACAGTGACGAACTATTTTCTGGTGAACCTGGCCTTCGCGAAC GCCTCCATGGCTGCATTCAATACAGTGGTGAACCTCACCTATGCTGTCCACAACGAAT GGTACTACGGCCTGTTCTACTGCAAGTTCACAACCTTCTTTCCCATCGCCGCTGTCTTC GCCAGTATCTGGTCCATGACGGCTGTGGCCTTTGATAGGTACATGGCCATCATAACATC CCCTCCAGCCCCGGCTGTCAGCCACAGCCACCAAAGTGGTCATCTGTGTCATCTGGGT CCTGGCTCTCCTGCTGGCCTTCCCCAGGGCTACTACTCAACCACAGAGACCATGCCC AGCAGAGTCGTGTGCATGATCGAATGGCCAGAGCATCCGAACAAGATTTATGAGAAA GTGTACCACATCTGTGTGACTGTGCTGATCTACTTCCTCCCCCTGCTGGTGATTGGCTA TGCATACACCGTAGTGGGAATCAGACTATGGGCTAGCAACATCTTCGAGATGCTGCGT ATCGATGAGGGAGGCGGCAGTGGCGGCGACGAGGCCGAAAAGTTGTTCAACCAGGA TGTGGACGCCGCCGTACGTGGAATTTTTCGTAACGCGAAGCTGAAGCCTGTCTATGAT

AGCCTGGATGCTGTCAGACGTGCAGCCCTGATTAACATGGTGTTCCAAATGGGCGAG
 ACGGGAGTCGCAGGCTTCACCAATTCGCTCAGGATGCTCCAGCAAAAGCGTTGGGAT
 GAAGCAGCGGTCAACTTGGCAAAGTCCAGATGGTACAACCAGACCCCTAACAGAGCC
 AAACGTGTGATCACCACCTTCAGGACCGGTACATGGGACGCTTACCACGAGCAAGTC
 TCTGCCAAGCGCAAGGTGGTCAAAATGATGATTGTCGTGGTGTGCACCTTCGCCATCT
 GCTGGCTGCCCTTCCACATCTTCTTCTCCTGCCCTACATCAACCCAGATCTCTACCTG
 AAGAAGTTTATCCAGCAGGTCTACCTGGCCATCATGTGGCTGGCCATGAGCTCCACCA
 TGTAACAACCCCATCATCTACTGCTGCCTCAATGACAGGTTCCGTCTGGGCTTCAAGCA
 TGCCTTCCGGTGCTGCCCTTCATCAGCGCCGGCGACTATGAGGGGCTGGAA

Primer sequences

pFastbac-N-F	ATTGGCGCGCCGGATAACGTCTCTCCCGGTG
pFastbac-C-R	AAAGGCCGGCCGGAGAGCACATTGGAGGAGAA
pFastbac-C-truncation-R	AAAGGCCGGCCTTCCAGCCCCTCATA
pcDNA3.1-N-F	GGAAAGCTTGCCACCATGGACTACAAGGACGATGATGAC GATAACGTCTCTCCCGGTGGA
pcDNA3.1-C-R	TCCGAATTCGGAGAGCACATTGGAGGAGAA
pcDNA3.1-C-truncation-R	TCCGAATTCCTTCCAGCCCCTCATAGTCGCC
ICL3-mT4L-N-F	ATCACTCTATGGGCTAGCAACATCTTCGAGATGCTG
ICL3-mT4L-N-R	CAGCATCTCGAAGATGTTGCTAGCCCATAGAGTGAT
ICL3-mT4L-C-F	GGTACATGGGACGCTTACCACGAGCAAGTCTCTGCC
ICL3-mT4L-C-R	GGCAGAGACTTGCTCGTGGTAAGCGTCCCATGTACC
E78 ^{2.50} D-F	GTGAACCTGGCCTTCGCGGACGCCTCCATGGCTGCATTC
E78 ^{2.50} D-R	GAATGCAGCCATGGAGGCGTCCGCGAAGGCCAGGTTAC
E78 ^{2.50} N-F	GTGAACCTGGCCTTCGCGAACGCCTCCATGGCTGCATTC
E78 ^{2.50} N-R	GAATGCAGCCATGGAGGCGTTCGCGAAGGCCAGGTTAC
I113 ^{3.33} M-F	CACAACCTCTTTCCCATGGCCGCTGTCTTCGCC
I113 ^{3.33} M-R	GGCGAAGACAGCGGCCATGGGAAAGAAGTTGTG
V116 ^{3.36} M-F	TTTCCCATCGCCGCTATGTTCCGCCAGTATCTAC
V116 ^{3.36} M-R	GTAGATACTGGCGAACATAGCGGCGATGGGAAA
Y121 ^{3.41} W-F	GTCTTCGCCAGTATCTGGTCCATGACGGCTGTG
Y121 ^{3.41} W-R	CACAGCCGTCATGGACCAGATACTGGCGAAGAC
Q165 ^{4.60} A-F	CTGCTGGCCTTCCCCGCCGGCTACTACTCAACC
Q165 ^{4.60} A-R	GGTTGAGTAGTAGCCGGCGGGGAAGGCCAGCAG
W184 ^{ECL2} L-F	GTGTGCATGATCGAACTGCCAGAGCATCCGAAC
W184 ^{ECL2} L-R	GTTCCGGATGCTCTGGCAGTTCGATCATGCACAC
E193 ^{5.35} H-F	CCGAACAAGATTTATCACAAAGTGTACCACATC
E193 ^{5.35} H-R	GATGTGGTACACTTTGTGATAAATCTTGTTCGG
H197 ^{5.39} L-F	TATGAGAAAGTGTACCTGATCTGTGTGACTGTG
H197 ^{5.39} L-R	CACAGTCACACAGATCAGGTACACTTTCTCATA
I204 ^{5.46} V-F	TGTGTGACTGTGCTGGTGTACTTCTCCCCCTG
I204 ^{5.46} V-R	CAGGGGGAGGAAGTACACCAGCACAGTCACACA
T222 ^{5.64} R-F	ACCGTAGTGGGAATCCGTCTATGGGCTAGC

T222 ^{5.64} R-R	GCTAGCCCATAGACGGATTCCCCTACTACGGT
F264 ^{6.51} Y-F	ATCTGCTGGCTGCCCTACCACATCTTCTTCCTC
F264 ^{6.51} Y-R	GAGGAAGAAGATGTGGTAGGGCAGCCAGCAGAT
F264 ^{6.51} L-F	ATCTGCTGGCTGCCCTCCACATCTTCTTCCTC
F264 ^{6.51} L-R	GAGGAAGAAGATGTGGAGGGGCAGCCAGCAGAT
N301 ^{7.49} Q-F	ATGAGCTCCACCATGTACCAGCCCATCATCTACTGCTGC
N301 ^{7.49} Q-R	GCAGCAGTAGATGATGGGCTGGTACATGGTGGAGCTCAT
N301 ^{7.49} E-F	ATGAGCTCCACCATGTACGAACCCATCATCTACTGCTGC
N301 ^{7.49} E-R	GCAGCAGTAGATGATGGGTTTCGTACATGGTGGAGCTCAT

Supplementary References

1. Johnson CE, Bovey FA. Calculation of Nuclear Magnetic Resonance Spectra of Aromatic Hydrocarbons. *J Chem Phys* **29**, 1012-1014 (1958).
2. Koradi R, Billeter M, Wuthrich K. MOLMOL: a program for display and analysis of macromolecular structures. *Journal of molecular graphics* **14**, 51-55, 29-32 (1996).